Claritev (CTEV) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
7 Aug, 2026Executive summary
Q2 2026 revenue grew 6.6% year-over-year to $257.5 million, driven by Claims Intelligence Solutions, with Adjusted EBITDA up 1.1% to $155.8 million and net revenue retention at 106.6%.
Bookings exceeded $70 million in the first half, on track for a $100 million full-year target, with 75–76% from upsell/cross-sell and five new client logos added.
Digital transformation and AI initiatives, including the Vision 2030 program, are accelerating operational efficiency and client value.
Leadership team is fully formed and executing with discipline for long-term growth.
Net loss narrowed to $59.2 million from $62.6 million in Q2 2025, with operating income up 41.2% to $23.4 million.
Financial highlights
Q2 2026 revenue: $257.5 million (+6.6% YoY); six-month revenue: $502.2 million (+6.2% YoY).
Adjusted EBITDA for Q2 2026 was $155.8 million (60.5% margin), and $302.7 million for the first half.
Operating cash flow for Q2 2026 was $92.7 million, up 51% year-over-year; free cash flow was $54.6 million, up 49%.
Adjusted EPS for Q2 2026 was $1.41, compared to a net loss per share of $(3.49).
Cash and equivalents at June 30, 2026: $14.4 million; total assets: $4.76 billion; total liabilities: $5.05 billion.
Outlook and guidance
Full-year 2026 revenue guidance raised to $1.00–$1.02 billion (4–6% growth); Adjusted EBITDA guidance increased to $610–$620 million (approx. 61% margin).
Free cash flow guidance raised to $5–$15 million for 2026; capital spend guidance unchanged at $160–$170 million.
Bookings expected to reach $100 million for the year, with pipeline exceeding $300 million.
Management expects sufficient liquidity for the next twelve months, supported by cash flow and $273.6 million available under the revolving credit facility.
Effective tax rate projected at 24–28%.
Latest events from Claritev
- Transformation drives growth, margin strength, and leadership in healthcare claims innovation.CTEV
Canaccord Genuity's 46th Annual Growth Conference - Record bookings, tech investment, and strong client ties drive ambitious 2030 growth targets.CTEV
Bank of America Global Healthcare Conference 2026 - Q1 2026 revenue grew 5.8% to $244.7M, with margin gains but continued net losses.CTEV
Q1 2026 - All proposals, including director elections and plan amendments, were approved without contest.CTEV
AGM 2026 - 2026 guidance targets $980M–$1B revenue, 61–62% EBITDA margin, and AI-driven growth.CTEV
Investor Day 2026 - Transformation and innovation drive growth, profitability, and expanded market reach.CTEV
44th Annual J.P. Morgan Healthcare Conference - Six new market segments, tech innovation, and a $200M pipeline drive growth into 2026.CTEV
BofA Securities Leveraged Finance Conference 2025 - Q1 2025 revenue was $231.3M, net loss narrowed, and transformation advanced.CTEV
Q1 2025 - 2024 net loss surged on a $1.49B impairment as transformation and rebranding drive long-term optimism.CTEV
Q4 2024